

---

## Standing Orders for Administering Trumenba Vaccine to Adolescents & Adults

---

**Purpose:** To reduce morbidity and mortality from meningococcal group B disease by vaccinating all children and teens who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.

**Policy:** Under these standing orders, eligible nurses and other healthcare professionals (e.g., pharmacists), where allowed by state law, may vaccinate children and teens who meet any of the criteria below.

### Procedure

1. Identify adolescents and adults in need of vaccination against meningococcal group B disease:
  - a. Trumenba vaccine is indicated for active immunization to prevent invasive disease caused by *Neisseria Meningitidis* serogroup B, approved for use in adolescents and adults age 10 through 25 years of age.
  - b. Anticipated first-year college student living in a residence hall and unvaccinated
  - c. Military recruits
2. Screen all patients for contraindications and precautions to vaccine:
  - a. **Contraindications:** a history of a serious allergic reaction (e.g., anaphylaxis) after a previous dose of Trumenba vaccine or to a meningococcal vaccine component. For information on vaccine components, refer to the manufacturer’s package insert ([www.immunize.org/packageinserts](http://www.immunize.org/packageinserts)) or go to [www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf).
  - b. **Precaution:** moderate or severe acute illness with or without fever
  - c. Individuals with weakened immune systems may have a reduced immune response
3. Provide all patients (or, in the case of a minor, parent or legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document in the patient’s medical record or office log, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).
4. Provide routine vaccination as follows: To adolescents or adults age 10 through 25 years of age, as a 3 dose series at months 0, 2, and 6.
5. Provide vaccination to children and teens with risk factors according to guidance on page 2 (“Meningococcal Vaccination Recommendations by Age and/or Risk Factor”).
6. Administer 0.5 mL of Trumenba vaccine intramuscularly in the deltoid muscle of the arm. Use a 22-25g needle. Choose needle length appropriate to the patient’s age and body mass.
7. Document each patient’s vaccine administration information and follow up in the following places:
  - a. **Medical chart:** Record the date the vaccine was administered, the manufacturer and lot number, the vaccination site and route, and the name and title of the person administering the vaccine. If vaccine was not given, record the reason(s) for non-receipt of the vaccine (e.g., medical contraindication, patient refusal).
  - b. **Personal information record card:** Record the date of vaccination and the name/location of the administering clinic
8. Be prepared for management of a medical emergency related to the administration of vaccine by having a written emergency medical protocol available, as well as equipment and medications. To prevent syncope in older children, vaccine patients while they are seated or lying down and consider observing them for 15 minutes after receipt of the vaccine.
9. Report all adverse reactions to Trumenba vaccine to the federal Vaccine Adverse Event Reporting System (VAERS) at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or by calling (800) 822-7967. VAERS report forms are available at [www.vaers.hhs.gov](http://www.vaers.hhs.gov)

